Conversely, there are no reports within clinical trials of QTc prolongation with bevacizumab, and a trial of 87 cancer patients treated with aflibercept, which has a higher affinity for binding VEGF, demonstrated a mean increase in QTc of only 8.4 ms [222]. The gene discussed is VEGFA; the disease is cancer.